Toronto Dominion Bank Acquires 14,601 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Toronto Dominion Bank increased its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 146.0% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 24,600 shares of the company’s stock after purchasing an additional 14,601 shares during the period. Toronto Dominion Bank’s holdings in Apellis Pharmaceuticals were worth $944,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Future Financial Wealth Managment LLC bought a new position in Apellis Pharmaceuticals during the first quarter worth about $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Apellis Pharmaceuticals during the first quarter worth about $89,000. nVerses Capital LLC grew its holdings in Apellis Pharmaceuticals by 300.0% during the second quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock worth $107,000 after purchasing an additional 2,100 shares during the period. CWA Asset Management Group LLC bought a new position in Apellis Pharmaceuticals during the fourth quarter worth about $205,000. Finally, Woodward Diversified Capital LLC acquired a new stake in Apellis Pharmaceuticals during the fourth quarter worth approximately $210,000. Institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on APLS shares. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. Mizuho cut their price objective on shares of Apellis Pharmaceuticals from $42.00 to $39.00 and set a “neutral” rating for the company in a research report on Friday, September 20th. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research report on Monday, September 23rd. Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating for the company in a research report on Tuesday, September 24th. Finally, Wedbush raised their price objective on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $70.20.

Apellis Pharmaceuticals Stock Down 2.1 %

NASDAQ APLS opened at $28.84 on Tuesday. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73. Apellis Pharmaceuticals, Inc. has a 1-year low of $28.33 and a 1-year high of $73.80. The company has a 50 day moving average of $37.01 and a 200-day moving average of $42.49. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -8.34 and a beta of 0.88.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million for the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.02) earnings per share. On average, equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Insider Activity at Apellis Pharmaceuticals

In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $3,623,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.80% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).